

**Clinical trial results:**

A phase III double-blind, cluster-randomized, controlled study to evaluate the impact on nasopharyngeal carriage, acute otitis media, immunogenicity and safety of GSK Biologicals' 10-valent pneumococcal and non-typeable Haemophilus influenzae protein D conjugate vaccine in children starting vaccination below 18 months of age.

Summary

EudraCT number	2008-006551-51
Trial protocol	FI
Global end of trial date	22 December 2011

Results information

Result version number	v2
This version publication date	12 March 2016
First version publication date	30 July 2015
Version creation reason	• New data added to full data set Data for secondary endpoints have been added.
Summary attachment (see zip file)	10PN-PD-DIT-053 results summary (10PN-PD-DIT-053 (112595) CTRS.pdf)

Trial information**Trial identification**

Sponsor protocol code	112595
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00839254
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	GlaxoSmithKline Biologicals
Sponsor organisation address	Rue de l'Institut 89, Rixensart, Belgium, B-1330
Public contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com
Scientific contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-000673-PIP01-09
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	22 April 2015
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	22 December 2011
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

- To demonstrate the effectiveness of 10Pn-PD-DiT vaccine in preventing culture-confirmed IPD due to vaccine pneumococcal serotypes in children vaccinated with at least one dose of 10Pn-PD-DiT within the first 7 months of life in clusters assigned to a 3-dose primary vaccination course.

Criteria for effectiveness:

Effectiveness (VE) in preventing culture-confirmed IPD due to the 10 vaccine serotypes will be demonstrated if the 2-sided p-value calculated for the null hypothesis $H_0 = (\text{vaccine-type [VT] IPD VE} = 0\%)$ is lower than 5%.

Refer to 10PN-PD-DIT-043 study (EudraCT number : 2008-005149-48).

Protection of trial subjects:

Vaccines were observed closely for at least 30 minutes following the administration of vaccines, with appropriate medical treatment readily available in case of a rare anaphylactic reaction.

Vaccines/products were administered only to eligible subjects that had no contraindications to any components of the vaccines/products. Subjects were followed up for serious adverse events (SAEs) reported as occurring during the study up to study end. An Independent Data Monitoring Committee (IDMC) was set up for this study to protect the ethical and safety interests of the subjects recruited, while securing as much as possible the scientific validity of the data. The IDMC was the same as in the 10PN-PD-DIT-043 study and will review safety data (SAEs) and all-cause mortality to identify potential treatment harm/benefit. Responsibilities of the IDMC included the following: 1) Review of data collection methods, safety/effectiveness monitoring procedures and making recommendations for additions or adjustments, as applicable.; 2) Recommendations for maintaining, or breaking the blind where necessary, in the course of reviewing the results; 3) Recommendations for stopping the trial for effectiveness or safety reasons when appropriate.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	18 February 2009
Long term follow-up planned	Yes
Long term follow-up rationale	Safety, Efficacy
Long term follow-up duration	9 Months
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Finland: 47364
Worldwide total number of subjects	47364
EEA total number of subjects	47364

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	47364
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

This study is linked with 10PN-PD-DIT-043 (111442) study (EudraCT: 2008-005149-48) with which primary objectives and endpoints are common. +/- 6000 subjects in this 10PN-PD-DIT-053 study contributed to primary objectives and endpoints results of the 10PN-PD-DIT-043 study as well as to some common secondary efficacy analyses.

Pre-assignment

Screening details:

Screening included check of inclusion/exclusion criteria & medical history, randomization, informed consent forms signing by parent(s)/legally accepted representative(s) (LAR[s]). Total population assessed for effectiveness is 47358 for analyses pooled across 10PN-PD-DIT-043 and 053 studies (41181 from 043 study + 6177 from 053 study).

Pre-assignment period milestones

Number of subjects started	47364
Number of subjects completed	6177

Pre-assignment subject non-completion reasons

Reason: Number of subjects	10PN-PD-DIT-043 subject participating to study: 41181
Reason: Number of subjects	Consent withdrawn by subject: 6

Period 1

Period 1 title	Overall Study Period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Blinding implementation details:

This study was conducted in a double-blind fashion for vaccine/control clusters applying the same 2+1 and 3+1 infant schedules. Study was run in an open fashion between infant schedules.

Arms

Are arms mutually exclusive?	Yes
Arm title	10Pn3+1-6W-6M/053 Group

Arm description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (112595) study only and aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (or 10Pn-PD-DiT, or 10Pn) vaccine according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.

Arm type	Experimental
Investigational medicinal product name	10-valent pneumococcal and non-typeable H. influenzae protein D conjugate vaccine
Investigational medicinal product code	10Pn-PD-DiT
Other name	10Pn, Synflorix
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Intramuscularly administration by injection in the thigh.

Arm title	10Pn2+1-6W-6M/053 Group
------------------	-------------------------

Arm description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (112595) study only and aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (or 10Pn-PD-DiT, or 10Pn) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.

Arm type	Experimental
Investigational medicinal product name	10-valent pneumococcal and non-typeable H. influenzae protein D conjugate vaccine
Investigational medicinal product code	10Pn-PD-DiT
Other name	10Pn, Synflorix
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Intramuscularly administration by injection in the thigh.

Arm title	Ctrl3+1-6W-6M/053 Group
------------------	-------------------------

Arm description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (112595) study only and aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B-thio free vaccine (or HBV vaccine) according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.

Arm type	Active comparator
Investigational medicinal product name	Engerix B-thio free
Investigational medicinal product code	
Other name	Engerix-B,HBV
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Intramuscularly administration by injection in the thigh.

Arm title	Ctrl2+1-6W-6M/053 Group
------------------	-------------------------

Arm description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (112595) study only and aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B-thio free vaccine (or HBV vaccine) according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule).

Arm type	Active comparator
Investigational medicinal product name	Engerix B-thio free
Investigational medicinal product code	
Other name	Engerix-B,HBV
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Intramuscularly administration by injection in the thigh.

Arm title	10Pn7-11M/053 Group
------------------	---------------------

Arm description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (112595) study only and aged 7 to 11 months at enrolment. Subjects received the Synflorix (or 10Pn-PD-DiT, or 10Pn) vaccine according to either a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (11-17M Schedule). The vaccine was administered intramuscularly in the thigh.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	10-valent pneumococcal and non-typeable H. influenzae protein D conjugate vaccine
Investigational medicinal product code	10Pn-PD-DiT
Other name	10Pn, Synflorix
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Intramuscularly administration by injection in the thigh.

Arm title	Ctrl7-11M/053 Group
------------------	---------------------

Arm description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (112595) study only and aged 7 to 11 months at enrolment. Subjects received the Engerix B-thio free (or HBV) vaccine according to either a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (11-17M Schedule). The vaccine was administered intramuscularly in the thigh.

Arm type	Active comparator
Investigational medicinal product name	Engerix B-thio free
Investigational medicinal product code	
Other name	Engerix-B,HBV
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Intramuscularly administration by injection in the thigh.

Arm title	10Pn12-18M/053 Group
------------------	----------------------

Arm description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (112595) study only and aged 12 to 18 months at enrolment. Subjects received the Synflorix (or 10Pn-PD-DiT, or 10Pn) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.

Arm type	Experimental
Investigational medicinal product name	10-valent pneumococcal and non-typeable H. influenzae protein D conjugate vaccine
Investigational medicinal product code	10Pn-PD-DiT
Other name	10Pn, Synflorix
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Intramuscularly administration by injection in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.

Arm title	Ctrl12-18M/053 Group
------------------	----------------------

Arm description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (112595) study only and aged 12 to 18 months at enrolment. Subjects received the Havrix-preservative free (or HAV) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.

Arm type	Active comparator
Investigational medicinal product name	Havrix-preservative free
Investigational medicinal product code	
Other name	HAV, Havrix 720 Junior
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Intramuscularly administration by injection in the thigh or in the deltoid region of upper arm, provided

the muscle size was adequate.

Number of subjects in period 1^[1]	10Pn3+1-6W-6M/053 Group	10Pn2+1-6W-6M/053 Group	Ctrl3+1-6W-6M/053 Group
Started	1849	1069	1316
Completed	1696	979	1224
Not completed	153	90	92
Consent withdrawn by subject	87	54	53
Physician decision	-	-	1
Adverse event, non-fatal	12	3	6
Withdrawn due to non-compliance	2	-	-
Wrong group allocation	-	-	-
Wrong treatment number allocation	-	-	1
Parents wanted to take pneumococcal vaccine	1	-	-
Lost to follow-up	51	32	30
Protocol deviation	-	1	1

Number of subjects in period 1^[1]	Ctrl2+1-6W-6M/053 Group	10Pn7-11M/053 Group	Ctrl7-11M/053 Group
Started	859	241	204
Completed	797	204	178
Not completed	62	37	26
Consent withdrawn by subject	32	27	15
Physician decision	-	-	-
Adverse event, non-fatal	5	2	1
Withdrawn due to non-compliance	-	-	-
Wrong group allocation	-	-	-
Wrong treatment number allocation	-	-	1
Parents wanted to take pneumococcal vaccine	-	-	1
Lost to follow-up	24	8	8
Protocol deviation	1	-	-

Number of subjects in period 1^[1]	10Pn12-18M/053 Group	Ctrl12-18M/053 Group
Started	368	271

Completed	340	256
Not completed	28	15
Consent withdrawn by subject	22	9
Physician decision	-	1
Adverse event, non-fatal	-	1
Withdrawn due to non-compliance	-	-
Wrong group allocation	1	-
Wrong treatment number allocation	-	-
Parents wanted to take pneumococcal vaccine	-	-
Lost to follow-up	4	2
Protocol deviation	1	2

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: 6183 subjects in total were enrolled in this study, out of which 6177 were actually vaccinated. In addition to these, 41181 subjects from 10PN-PD-DIT-043 (111442) study also participated to this study to some efficacy analyses (including the primary analysis for this study which is common with 10PN-PD-DIT-043 (111442) study).

Baseline characteristics

Reporting groups

Reporting group title	10Pn3+1-6W-6M/053 Group
-----------------------	-------------------------

Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (112595) study only and aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (or 10Pn-PD-DiT, or 10Pn) vaccine according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.

Reporting group title	10Pn2+1-6W-6M/053 Group
-----------------------	-------------------------

Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (112595) study only and aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (or 10Pn-PD-DiT, or 10Pn) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.

Reporting group title	Ctrl3+1-6W-6M/053 Group
-----------------------	-------------------------

Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (112595) study only and aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B-thio free vaccine (or HBV vaccine) according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.

Reporting group title	Ctrl2+1-6W-6M/053 Group
-----------------------	-------------------------

Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (112595) study only and aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B-thio free vaccine (or HBV vaccine) according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule).

Reporting group title	10Pn7-11M/053 Group
-----------------------	---------------------

Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (112595) study only and aged 7 to 11 months at enrolment. Subjects received the Synflorix (or 10Pn-PD-DiT, or 10Pn) vaccine according to either a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (11-17M Schedule). The vaccine was administered intramuscularly in the thigh.

Reporting group title	Ctrl7-11M/053 Group
-----------------------	---------------------

Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (112595) study only and aged 7 to 11 months at enrolment. Subjects received the Engerix B-thio free (or HBV) vaccine according to either a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (11-17M Schedule). The vaccine was administered intramuscularly in the thigh.

Reporting group title	10Pn12-18M/053 Group
-----------------------	----------------------

Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (112595) study only and aged 12 to 18 months at enrolment. Subjects received the Synflorix (or 10Pn-PD-DiT, or 10Pn) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.

Reporting group title	Ctrl12-18M/053 Group
-----------------------	----------------------

Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (112595) study only and aged 12 to 18 months at enrolment. Subjects received the Havrix-preservative free (or HAV) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M

Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.

Reporting group values	10Pn3+1-6W-6M/053 Group	10Pn2+1-6W-6M/053 Group	Ctrl3+1-6W-6M/053 Group
Number of subjects	1849	1069	1316
Age categorical Units: Subjects			
Infants and toddlers (28 days-23 months)	1849	1069	1316
Age continuous Units: months			
arithmetic mean	2.4	2.6	2.3
standard deviation	± 1.02	± 1.19	± 0.95
Gender categorical Units: Subjects			
Female	921	551	681
Male	928	518	635

Reporting group values	Ctrl2+1-6W-6M/053 Group	10Pn7-11M/053 Group	Ctrl7-11M/053 Group
Number of subjects	859	241	204
Age categorical Units: Subjects			
Infants and toddlers (28 days-23 months)	859	241	204
Age continuous Units: months			
arithmetic mean	2.4	9	8.7
standard deviation	± 1	± 1.44	± 1.39
Gender categorical Units: Subjects			
Female	393	118	113
Male	466	123	91

Reporting group values	10Pn12-18M/053 Group	Ctrl12-18M/053 Group	Total
Number of subjects	368	271	6177
Age categorical Units: Subjects			
Infants and toddlers (28 days-23 months)	368	271	6177
Age continuous Units: months			
arithmetic mean	15	15.2	-
standard deviation	± 1.99	± 1.99	-
Gender categorical Units: Subjects			
Female	173	142	3092
Male	195	129	3085

End points

End points reporting groups

Reporting group title	10Pn3+1-6W-6M/053 Group
Reporting group description: Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (112595) study only and aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (or 10Pn-PD-DiT, or 10Pn) vaccine according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.	
Reporting group title	10Pn2+1-6W-6M/053 Group
Reporting group description: Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (112595) study only and aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (or 10Pn-PD-DiT, or 10Pn) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.	
Reporting group title	Ctrl3+1-6W-6M/053 Group
Reporting group description: Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (112595) study only and aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B-thio free vaccine (or HBV vaccine) according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.	
Reporting group title	Ctrl2+1-6W-6M/053 Group
Reporting group description: Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (112595) study only and aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B-thio free vaccine (or HBV vaccine) according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule).	
Reporting group title	10Pn7-11M/053 Group
Reporting group description: Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (112595) study only and aged 7 to 11 months at enrolment. Subjects received the Synflorix (or 10Pn-PD-DiT, or 10Pn) vaccine according to either a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (11-17M Schedule). The vaccine was administered intramuscularly in the thigh.	
Reporting group title	Ctrl7-11M/053 Group
Reporting group description: Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (112595) study only and aged 7 to 11 months at enrolment. Subjects received the Engerix B-thio free (or HBV) vaccine according to either a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (11-17M Schedule). The vaccine was administered intramuscularly in the thigh.	
Reporting group title	10Pn12-18M/053 Group
Reporting group description: Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (112595) study only and aged 12 to 18 months at enrolment. Subjects received the Synflorix (or 10Pn-PD-DiT, or 10Pn) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.	
Reporting group title	Ctrl12-18M/053 Group
Reporting group description: Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (112595) study only and aged 12 to 18 months at enrolment. Subjects received the Havrix-preservative free (or HAV) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M	

Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.

Subject analysis set title	10Pn3+1-6W-6M/043+053 Group
Subject analysis set type	Per protocol

Subject analysis set description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (111442) and 10PN-PD-DIT (112595) studies, pooled, and aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (or 10Pn-PD-DiT, or 10Pn) vaccine according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). Refer to group description for 10Pn3+1-6W-6M/053 Group for details on vaccine specifics and administration route in this group.

Subject analysis set title	10Pn2+1-6W-6M/043+053 Group
Subject analysis set type	Per protocol

Subject analysis set description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (111442) and 10PN-PD-DIT (112595) studies, pooled, and aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (or 10Pn-PD-DiT, or 10Pn) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). Refer to group description for 10Pn2+1-6W-6M/053 Group for details on vaccine specifics and administration route in this group.

Subject analysis set title	Ctrl-6W-6M/043+053 Group
Subject analysis set type	Per protocol

Subject analysis set description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (111442) and 10PN-PD-DIT (112595) studies, pooled, and aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B-thio free vaccine (or HBV vaccine) according to either a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule), or according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). Refer to group descriptions for Ctrl3+1-6W-6M/053 and Ctrl3+1-6W-6M/053 groups for details on vaccine specifics and administration route in this group.

Subject analysis set title	10Pn7-11M/043+053 Group
Subject analysis set type	Per protocol

Subject analysis set description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (111442) and 10PN-PD-DIT (112595) studies, pooled, and aged 7 to 11 months at enrolment. Subjects received the Synflorix (or 10Pn-PD-DiT, or 10Pn) vaccine according to either a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (11-17M Schedule). Refer to group description for 10Pn7-11M/053 Group for details on vaccine specifics and administration route in this group.

Subject analysis set title	Ctrl7-11M/043+053 Group
Subject analysis set type	Per protocol

Subject analysis set description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (111442) and 10PN-PD-DIT (112595) studies, pooled, and aged 7 to 11 months at enrolment. Subjects received the Engerix B-thio free (or HBV) vaccine according to either a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (11-17M Schedule). Refer to group description for Ctrl7-11M/053 Group for details on vaccine specifics and administration route in this group.

Subject analysis set title	10Pn12-18M/043+053 Group
Subject analysis set type	Per protocol

Subject analysis set description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (111442) and 10PN-PD-DIT (112595) studies, pooled, aged 12 to 18 months at enrolment. Subjects received the Synflorix (or 10Pn-PD-DiT, or 10Pn) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). Refer to group description for 10Pn12-18M/053 Group for details on vaccine specifics and administration route in this group.

Subject analysis set title	Ctrl12-18M/043+053
Subject analysis set type	Per protocol

Subject analysis set description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (111442) and 10PN-PD-DIT (112595) studies, pooled, and aged 12 to 18 months at enrolment. Subjects received the Synflorix (or 10PN-PD-DiT, or 10Pn) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). Refer to group description for Ctrl12-18M/053 Group for details on vaccine specifics and administration route in this group.

Primary: PYAR as regards subjects with culture-confirmed (CC) cases of IPD due to pneumococcal vaccine serotypes (VT-IPD), across all serotypes. In subjects receiving 3+1 Infant Schedule of 10Pn

End point title	PYAR as regards subjects with culture-confirmed (CC) cases of IPD due to pneumococcal vaccine serotypes (VT-IPD), across all serotypes. In subjects receiving 3+1 Infant Schedule of 10Pn
-----------------	---

End point description:

The PYAR (Person-Year Rate) as regards subjects with culture-confirmed invasive pneumococcal disease (IPD) due to any of the pneumococcal vaccine serotypes was tabulated (vaccine pneumococcal serotypes = serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F). PYAR was calculated as follows n (= number of subjects reported with event) divided by T (= sum of follow-up period expressed in years) (per 1000).

End point type	Primary
----------------	---------

End point timeframe:

Period of follow-up was any time after the administration of first vaccine dose till the end of the blinded invasive disease (ID) Follow-up period.

End point values	10Pn3+1-6W-6M/043+053 Group	Ctrl-6W-6M/043+053 Group		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	10273	10201		
Units: PYAR				
arithmetic mean (confidence interval 95%)				
PYAR IPD Pneumococcal	0 (0 to 0.172)	0.564 (0.291 to 0.984)		

Statistical analyses

Statistical analysis title	VE at preventing culture-confirmed IPD
----------------------------	--

Statistical analysis description:

The analysis aimed at providing an estimate of vaccine effectiveness (VE) at preventing culture-confirmed IPD by comparing PYARs between groups taking into account the following parameters: T , n , $n+$ (number of clusters with at least one event culture-confirmed ID), and n/T . VE of the 10Pn vaccine in preventing culture-confirmed IPD due to the 10 vaccine serotypes was demonstrated if the 2-sided p -value calculated for the null hypothesis $H_0 = (\text{vaccine-type [VT] IPD VE} = 0\%)$ was lower than ($<$) 5%.

Comparison groups	10Pn3+1-6W-6M/043+053 Group v Ctrl-6W-6M/043+053 Group
-------------------	--

Number of subjects included in analysis	20474
Analysis specification	Pre-specified
Analysis type	superiority ^[1]
P-value	< 0.0001 ^[2]
Method	Regression, Linear
Parameter estimate	VE (1-RR)
Point estimate	100
Confidence interval	
level	95 %
sides	2-sided
lower limit	82.8
upper limit	100

Notes:

[1] - VE (defined as 1 minus Relative Risk (RR)) was calculated by comparing numbers of culture-confirmed IPD. The number of subjects with IPD in each cluster was compared between groups (10PN3+1 vs Control). This comparison was done using a negative binomial log-linear model with correction for dispersion group- and cluster-related effect. Over-dispersion being assessed was null, a standard Poisson model methodology was applied including the group and cluster stratification factors as covariates.

[2] - P-value was calculated using a classical log linear Poisson regression with strata, without taking into account the multiplicity of the endpoints.

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Solicited and unsolicited AEs: 4-day (Days 0-3) and 31-day (Days 0-30) post primary (PRI)/booster (BST) vaccination dose(s); SAEs: from day to study end, Month (M) 18 for 6W-6M groups, M16 for 7-11M groups and M9 for M12-18 groups.

Adverse event reporting additional description:

To avoid inconsistency between the AE reporting and the acute otitis media (AOM) questionnaire filled in by subjects' parent(s)/LAR(s), otitis was not reported as an AE if already reported via the AOM questionnaire. The occurrence of reported AEs (all/related) was not available and is encoded as equal to the number of subjects affected.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	15.0

Reporting groups

Reporting group title	10Pn3+1-6W-6M/053 Group
-----------------------	-------------------------

Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (112595) study only and aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (or 10Pn-PD-DiT, or 10Pn) vaccine according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.

Reporting group title	Ctrl3+1-6W-6M/053 Group
-----------------------	-------------------------

Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (112595) study only and aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B-thio free vaccine (or HBV vaccine) according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.

Reporting group title	10Pn2+1-6W-6M/053 Group
-----------------------	-------------------------

Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (112595) study only and aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (or 10Pn-PD-DiT, or 10Pn) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.

Reporting group title	Ctrl2+1-6W-6M/053 Group
-----------------------	-------------------------

Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (112595) study only and aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B-thio free vaccine (or HBV vaccine) according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule).

Reporting group title	10Pn7-11M/053 Group
-----------------------	---------------------

Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (112595) study only and aged 7 to 11 months at enrolment. Subjects received the Synflorix (or 10Pn-PD-DiT, or 10Pn) vaccine according to either a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (11-17M Schedule). The vaccine was administered intramuscularly in the thigh.

Reporting group title	Ctrl7-11M/053 Group
-----------------------	---------------------

Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (112595) study only and aged 7

to 11 months at enrolment. Subjects received the Engerix B-thio free (or HBV) vaccine according to either a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (11-17M Schedule). The vaccine was administered intramuscularly in the thigh.

Reporting group title	10Pn12-18M/053 Group
-----------------------	----------------------

Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (112595) study only and aged 12 to 18 months at enrolment. Subjects received the Synflorix (or 10Pn-PD-DiT, or 10Pn) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.

Reporting group title	Ctrl12-18M/053 Group
-----------------------	----------------------

Reporting group description:

Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (112595) study only and aged 12 to 18 months at enrolment. Subjects received the Havrix-preservative free (or HAV) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.

Serious adverse events	10Pn3+1-6W-6M/053 Group	Ctrl3+1-6W-6M/053 Group	10Pn2+1-6W-6M/053 Group
Total subjects affected by serious adverse events			
subjects affected / exposed	163 / 1849 (8.82%)	77 / 1069 (7.20%)	97 / 1316 (7.37%)
number of deaths (all causes)	0	0	1
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Haemangioma			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	1 / 1316 (0.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	4 / 1849 (0.22%)	4 / 1069 (0.37%)	4 / 1316 (0.30%)
occurrences causally related to treatment / all	1 / 4	0 / 4	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Crying			

subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	1 / 1316 (0.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Developmental delay			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sudden death			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	1 / 1316 (0.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Immune system disorders			
Milk allergy			
subjects affected / exposed	1 / 1849 (0.05%)	1 / 1069 (0.09%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaphylactic reaction			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	4 / 1849 (0.22%)	4 / 1069 (0.37%)	2 / 1316 (0.15%)
occurrences causally related to treatment / all	0 / 4	0 / 4	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 1849 (0.00%)	1 / 1069 (0.09%)	2 / 1316 (0.15%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Apnoea			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cough			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Breath holding			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Confusional state			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Cardiac murmur			
subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Concussion			
subjects affected / exposed	3 / 1849 (0.16%)	0 / 1069 (0.00%)	2 / 1316 (0.15%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Contusion			
subjects affected / exposed	0 / 1849 (0.00%)	1 / 1069 (0.09%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electric shock			
subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			

subjects affected / exposed	2 / 1849 (0.11%)	2 / 1069 (0.19%)	1 / 1316 (0.08%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Burns second degree			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	1 / 1316 (0.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chemical poisoning			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	1 / 1316 (0.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skull fracture			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Accidental drug intake by child			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Accidental poisoning			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foreign body			
subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	2 / 1316 (0.15%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint dislocation			
subjects affected / exposed	0 / 1849 (0.00%)	1 / 1069 (0.09%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Poisoning			

subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thermal burn			
subjects affected / exposed	0 / 1849 (0.00%)	1 / 1069 (0.09%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia Fracture			
subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Amaurotic familial idiocy			
subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Combined immunodeficiency			
subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Craniosynostosis			
subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngomalacia			
subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Patent ductus arteriosus			
subjects affected / exposed	2 / 1849 (0.11%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyloric stenosis			

subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular septal defect			
subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	1 / 1316 (0.08%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coarctation of the aorta			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	1 / 1316 (0.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Krabbe's disease			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mitochondrial encephalomyopathy			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cyanosis			
subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	1 / 1316 (0.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Convulsion			
subjects affected / exposed	5 / 1849 (0.27%)	2 / 1069 (0.19%)	2 / 1316 (0.15%)
occurrences causally related to treatment / all	2 / 5	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			

subjects affected / exposed	0 / 1849 (0.00%)	1 / 1069 (0.09%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile convulsion			
subjects affected / exposed	5 / 1849 (0.27%)	1 / 1069 (0.09%)	6 / 1316 (0.46%)
occurrences causally related to treatment / all	0 / 5	0 / 1	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperreflexia			
subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Loss of consciousness			
subjects affected / exposed	0 / 1849 (0.00%)	1 / 1069 (0.09%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorder			
subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Petit mal epilepsy			
subjects affected / exposed	0 / 1849 (0.00%)	1 / 1069 (0.09%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Altered state of consciousness			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Balance disorder			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	1 / 1316 (0.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral infarction			

subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	1 / 1316 (0.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cognitive disorder			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysarthria			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Aplasia pure red cell			
subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenitis			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	1 / 1849 (0.05%)	1 / 1069 (0.09%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enteritis			
subjects affected / exposed	2 / 1849 (0.11%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 1849 (0.00%)	1 / 1069 (0.09%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia strangulated			

subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intussusception			
subjects affected / exposed	2 / 1849 (0.11%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Melaena			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Erythema			
subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urticaria			
subjects affected / exposed	0 / 1849 (0.00%)	1 / 1069 (0.09%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eczema nummular			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Juvenile arthritis			
subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Neck pain			
subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abscess neck			
subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenovirus infection			
subjects affected / exposed	2 / 1849 (0.11%)	1 / 1069 (0.09%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal abscess			
subjects affected / exposed	1 / 1849 (0.05%)	1 / 1069 (0.09%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial infection			
subjects affected / exposed	0 / 1849 (0.00%)	2 / 1069 (0.19%)	1 / 1316 (0.08%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial sepsis			
subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiolitis			
subjects affected / exposed	9 / 1849 (0.49%)	5 / 1069 (0.47%)	8 / 1316 (0.61%)
occurrences causally related to treatment / all	0 / 9	0 / 5	0 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	33 / 1849 (1.78%)	19 / 1069 (1.78%)	13 / 1316 (0.99%)
occurrences causally related to treatment / all	0 / 33	0 / 19	0 / 13
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Croup infectious			

subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear infection			
subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterovirus infection			
subjects affected / exposed	2 / 1849 (0.11%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	15 / 1849 (0.81%)	5 / 1069 (0.47%)	7 / 1316 (0.53%)
occurrences causally related to treatment / all	0 / 15	0 / 5	0 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis adenovirus			
subjects affected / exposed	0 / 1849 (0.00%)	1 / 1069 (0.09%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis rotavirus			
subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Groin abscess			
subjects affected / exposed	0 / 1849 (0.00%)	1 / 1069 (0.09%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
H1N1 influenza			

subjects affected / exposed	2 / 1849 (0.11%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 1849 (0.00%)	1 / 1069 (0.09%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	2 / 1849 (0.11%)	1 / 1069 (0.09%)	1 / 1316 (0.08%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	1 / 1316 (0.08%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngitis			
subjects affected / exposed	12 / 1849 (0.65%)	4 / 1069 (0.37%)	6 / 1316 (0.46%)
occurrences causally related to treatment / all	0 / 12	0 / 4	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngitis viral			
subjects affected / exposed	0 / 1849 (0.00%)	1 / 1069 (0.09%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymph gland infection			
subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningococcal sepsis			
subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media			

subjects affected / exposed	22 / 1849 (1.19%)	9 / 1069 (0.84%)	7 / 1316 (0.53%)
occurrences causally related to treatment / all	0 / 22	0 / 9	0 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media acute			
subjects affected / exposed	5 / 1849 (0.27%)	1 / 1069 (0.09%)	2 / 1316 (0.15%)
occurrences causally related to treatment / all	0 / 5	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngitis			
subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumococcal bacteraemia			
subjects affected / exposed	0 / 1849 (0.00%)	1 / 1069 (0.09%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumococcal infection			
subjects affected / exposed	0 / 1849 (0.00%)	1 / 1069 (0.09%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumococcal sepsis			
subjects affected / exposed	0 / 1849 (0.00%)	2 / 1069 (0.19%)	1 / 1316 (0.08%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	10 / 1849 (0.54%)	3 / 1069 (0.28%)	5 / 1316 (0.38%)
occurrences causally related to treatment / all	0 / 10	0 / 3	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial			
subjects affected / exposed	0 / 1849 (0.00%)	1 / 1069 (0.09%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia respiratory syncytial viral			

subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	2 / 1316 (0.15%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	10 / 1849 (0.54%)	2 / 1069 (0.19%)	7 / 1316 (0.53%)
occurrences causally related to treatment / all	0 / 10	0 / 2	0 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis acute			
subjects affected / exposed	4 / 1849 (0.22%)	1 / 1069 (0.09%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus bronchiolitis			
subjects affected / exposed	11 / 1849 (0.59%)	4 / 1069 (0.37%)	7 / 1316 (0.53%)
occurrences causally related to treatment / all	0 / 11	0 / 4	0 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus bronchitis			
subjects affected / exposed	0 / 1849 (0.00%)	2 / 1069 (0.19%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus infection			
subjects affected / exposed	4 / 1849 (0.22%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection viral			
subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	2 / 1849 (0.11%)	2 / 1069 (0.19%)	1 / 1316 (0.08%)
occurrences causally related to treatment / all	1 / 2	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal sepsis			

subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	1 / 1316 (0.08%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis			
subjects affected / exposed	2 / 1849 (0.11%)	0 / 1069 (0.00%)	2 / 1316 (0.15%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tracheitis			
subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	5 / 1849 (0.27%)	3 / 1069 (0.28%)	3 / 1316 (0.23%)
occurrences causally related to treatment / all	0 / 5	0 / 3	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	2 / 1849 (0.11%)	1 / 1069 (0.09%)	2 / 1316 (0.15%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	1 / 1849 (0.05%)	4 / 1069 (0.37%)	3 / 1316 (0.23%)
occurrences causally related to treatment / all	0 / 1	0 / 4	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	1 / 1316 (0.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eczema infected			

subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	1 / 1316 (0.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Exanthema subitum			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	1 / 1316 (0.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis norovirus			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	1 / 1316 (0.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hand-foot-and-mouth disease			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	1 / 1316 (0.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Impetigo			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lobar pneumonia			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	1 / 1316 (0.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mastoiditis			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	1 / 1316 (0.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	1 / 1316 (0.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parainfluenzae virus infection			

subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	1 / 1316 (0.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	1 / 1316 (0.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic arthritis streptococcal			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varicella			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	1 / 1316 (0.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea infectious			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia sepsis			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media fungal			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia viral			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Roseola			

subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rotavirus infection			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis orbital			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous abscess			
subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Type 1 diabetes mellitus			
subjects affected / exposed	1 / 1849 (0.05%)	0 / 1069 (0.00%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Weight gain poor			
subjects affected / exposed	0 / 1849 (0.00%)	1 / 1069 (0.09%)	0 / 1316 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			

subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	2 / 1316 (0.15%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemia			
subjects affected / exposed	0 / 1849 (0.00%)	0 / 1069 (0.00%)	1 / 1316 (0.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Ctrl2+1-6W-6M/053 Group	10Pn7-11M/053 Group	Ctrl7-11M/053 Group
Total subjects affected by serious adverse events			
subjects affected / exposed	74 / 859 (8.61%)	24 / 241 (9.96%)	18 / 204 (8.82%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Haemangioma			
subjects affected / exposed	1 / 859 (0.12%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	2 / 859 (0.23%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Crying			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Developmental delay			

subjects affected / exposed	1 / 859 (0.12%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sudden death			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Milk allergy			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaphylactic reaction			
subjects affected / exposed	1 / 859 (0.12%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	3 / 859 (0.35%)	4 / 241 (1.66%)	1 / 204 (0.49%)
occurrences causally related to treatment / all	0 / 3	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Apnoea			
subjects affected / exposed	1 / 859 (0.12%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cough			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	1 / 204 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Psychiatric disorders			
Breath holding			
subjects affected / exposed	1 / 859 (0.12%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Confusional state			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Cardiac murmur			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Concussion			
subjects affected / exposed	2 / 859 (0.23%)	1 / 241 (0.41%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Contusion			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electric shock			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	1 / 859 (0.12%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Burns second degree			

subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chemical poisoning			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skull fracture			
subjects affected / exposed	1 / 859 (0.12%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Accidental drug intake by child			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Accidental poisoning			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foreign body			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint dislocation			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Poisoning			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thermal burn			

subjects affected / exposed	1 / 859 (0.12%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia Fracture			
subjects affected / exposed	1 / 859 (0.12%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Amaurotic familial idiocy			
subjects affected / exposed	1 / 859 (0.12%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Combined immunodeficiency			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Craniosynostosis			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngomalacia			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Patent ductus arteriosus			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyloric stenosis			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular septal defect			

subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coarctation of the aorta			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Krabbe's disease			
subjects affected / exposed	1 / 859 (0.12%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mitochondrial encephalomyopathy			
subjects affected / exposed	1 / 859 (0.12%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cyanosis			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Convulsion			
subjects affected / exposed	1 / 859 (0.12%)	1 / 241 (0.41%)	1 / 204 (0.49%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			
subjects affected / exposed	0 / 859 (0.00%)	1 / 241 (0.41%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile convulsion			

subjects affected / exposed	2 / 859 (0.23%)	0 / 241 (0.00%)	1 / 204 (0.49%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperreflexia			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Loss of consciousness			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorder			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Petit mal epilepsy			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Altered state of consciousness			
subjects affected / exposed	1 / 859 (0.12%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Balance disorder			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral infarction			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cognitive disorder			

subjects affected / exposed	1 / 859 (0.12%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysarthria			
subjects affected / exposed	1 / 859 (0.12%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Aplasia pure red cell			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenitis			
subjects affected / exposed	1 / 859 (0.12%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	0 / 859 (0.00%)	1 / 241 (0.41%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enteritis			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia strangulated			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intussusception			

subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Melaena			
subjects affected / exposed	1 / 859 (0.12%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Erythema			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urticaria			
subjects affected / exposed	1 / 859 (0.12%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eczema nummular			
subjects affected / exposed	1 / 859 (0.12%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Juvenile arthritis			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neck pain			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Infections and infestations Abscess neck subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 0 / 859 (0.00%) 0 / 0 0 / 0	 0 / 241 (0.00%) 0 / 0 0 / 0	 0 / 204 (0.00%) 0 / 0 0 / 0
Adenovirus infection subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 0 / 859 (0.00%) 0 / 0 0 / 0	 0 / 241 (0.00%) 0 / 0 0 / 0	 0 / 204 (0.00%) 0 / 0 0 / 0
Anal abscess subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 0 / 859 (0.00%) 0 / 0 0 / 0	 0 / 241 (0.00%) 0 / 0 0 / 0	 0 / 204 (0.00%) 0 / 0 0 / 0
Bacterial infection subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 0 / 859 (0.00%) 0 / 0 0 / 0	 1 / 241 (0.41%) 0 / 1 0 / 0	 0 / 204 (0.00%) 0 / 0 0 / 0
Bacterial sepsis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 0 / 859 (0.00%) 0 / 0 0 / 0	 0 / 241 (0.00%) 0 / 0 0 / 0	 1 / 204 (0.49%) 0 / 1 0 / 0
Bronchiolitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 9 / 859 (1.05%) 0 / 9 0 / 0	 1 / 241 (0.41%) 0 / 1 0 / 0	 2 / 204 (0.98%) 0 / 2 0 / 0
Bronchitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 20 / 859 (2.33%) 0 / 20 0 / 0	 9 / 241 (3.73%) 0 / 9 0 / 0	 5 / 204 (2.45%) 0 / 5 0 / 0
Croup infectious subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	 0 / 859 (0.00%) 0 / 0 0 / 0	 0 / 241 (0.00%) 0 / 0 0 / 0	 0 / 204 (0.00%) 0 / 0 0 / 0
Ear infection			

subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterovirus infection			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	4 / 859 (0.47%)	3 / 241 (1.24%)	1 / 204 (0.49%)
occurrences causally related to treatment / all	0 / 4	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis adenovirus			
subjects affected / exposed	0 / 859 (0.00%)	1 / 241 (0.41%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis rotavirus			
subjects affected / exposed	0 / 859 (0.00%)	1 / 241 (0.41%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	0 / 859 (0.00%)	1 / 241 (0.41%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Groin abscess			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
H1N1 influenza			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			

subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngitis			
subjects affected / exposed	7 / 859 (0.81%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 7	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngitis viral			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymph gland infection			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningococcal sepsis			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media			
subjects affected / exposed	13 / 859 (1.51%)	1 / 241 (0.41%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 13	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media acute			

subjects affected / exposed	3 / 859 (0.35%)	2 / 241 (0.83%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngitis			
subjects affected / exposed	0 / 859 (0.00%)	1 / 241 (0.41%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumococcal bacteraemia			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumococcal infection			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumococcal sepsis			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	5 / 859 (0.58%)	1 / 241 (0.41%)	1 / 204 (0.49%)
occurrences causally related to treatment / all	0 / 5	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia respiratory syncytial viral			
subjects affected / exposed	1 / 859 (0.12%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			

subjects affected / exposed	2 / 859 (0.23%)	0 / 241 (0.00%)	1 / 204 (0.49%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis acute			
subjects affected / exposed	3 / 859 (0.35%)	0 / 241 (0.00%)	2 / 204 (0.98%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus bronchiolitis			
subjects affected / exposed	4 / 859 (0.47%)	1 / 241 (0.41%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus bronchitis			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	1 / 204 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus infection			
subjects affected / exposed	2 / 859 (0.23%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection viral			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	2 / 859 (0.23%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal sepsis			
subjects affected / exposed	1 / 859 (0.12%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis			

subjects affected / exposed	0 / 859 (0.00%)	1 / 241 (0.41%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tracheitis			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	3 / 859 (0.35%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	1 / 859 (0.12%)	0 / 241 (0.00%)	1 / 204 (0.49%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	1 / 859 (0.12%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	1 / 859 (0.12%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eczema infected			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Exanthema subitum			

subjects affected / exposed	0 / 859 (0.00%)	1 / 241 (0.41%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis norovirus			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hand-foot-and-mouth disease			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Impetigo			
subjects affected / exposed	1 / 859 (0.12%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lobar pneumonia			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mastoiditis			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parainfluenzae virus infection			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			

subjects affected / exposed	0 / 859 (0.00%)	1 / 241 (0.41%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic arthritis streptococcal			
subjects affected / exposed	1 / 859 (0.12%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varicella			
subjects affected / exposed	1 / 859 (0.12%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea infectious			
subjects affected / exposed	0 / 859 (0.00%)	1 / 241 (0.41%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia sepsis			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	1 / 204 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media fungal			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	1 / 204 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia viral			
subjects affected / exposed	0 / 859 (0.00%)	1 / 241 (0.41%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Roseola			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	1 / 204 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rotavirus infection			

subjects affected / exposed	0 / 859 (0.00%)	1 / 241 (0.41%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis orbital			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous abscess			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Type 1 diabetes mellitus			
subjects affected / exposed	1 / 859 (0.12%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Weight gain poor			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemia			

subjects affected / exposed	0 / 859 (0.00%)	0 / 241 (0.00%)	0 / 204 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	10Pn12-18M/053 Group	Ctrl12-18M/053 Group	
Total subjects affected by serious adverse events			
subjects affected / exposed	23 / 368 (6.25%)	14 / 271 (5.17%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Haemangioma			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Crying			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Developmental delay			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden death			

subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Milk allergy			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaphylactic reaction			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	4 / 368 (1.09%)	2 / 271 (0.74%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Apnoea			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cough			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Breath holding			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Confusional state			
subjects affected / exposed	0 / 368 (0.00%)	1 / 271 (0.37%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Cardiac murmur			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Concussion			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Contusion			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electric shock			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femur fracture			
subjects affected / exposed	1 / 368 (0.27%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Burns second degree			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chemical poisoning			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Skull fracture			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Accidental drug intake by child			
subjects affected / exposed	1 / 368 (0.27%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Accidental poisoning			
subjects affected / exposed	1 / 368 (0.27%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foreign body			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint dislocation			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Poisoning			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thermal burn			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tibia Fracture			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital, familial and genetic disorders			

Amaurotic familial idiocy			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Combined immunodeficiency			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Craniosynostosis			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngomalacia			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Patent ductus arteriosus			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyloric stenosis			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular septal defect			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coarctation of the aorta			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Krabbe's disease			

subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mitochondrial encephalomyopathy			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Cyanosis			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericardial effusion			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Convulsion			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epilepsy			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile convulsion			
subjects affected / exposed	2 / 368 (0.54%)	1 / 271 (0.37%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperreflexia			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Loss of consciousness			

subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorder			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Petit mal epilepsy			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Altered state of consciousness			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Balance disorder			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral infarction			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cognitive disorder			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysarthria			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Aplasia pure red cell			

subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenitis			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enteritis			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia strangulated			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intussusception			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Melaena			

subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Erythema			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urticaria			
subjects affected / exposed	0 / 368 (0.00%)	1 / 271 (0.37%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eczema nummular			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Juvenile arthritis			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neck pain			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Abscess neck			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenovirus infection			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Anal abscess			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial infection			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial sepsis			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchiolitis			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			
subjects affected / exposed	5 / 368 (1.36%)	2 / 271 (0.74%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Croup infectious			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear infection			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterovirus infection			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			

subjects affected / exposed	2 / 368 (0.54%)	1 / 271 (0.37%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis adenovirus			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis rotavirus			
subjects affected / exposed	1 / 368 (0.27%)	1 / 271 (0.37%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis viral			
subjects affected / exposed	2 / 368 (0.54%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Groin abscess			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
H1N1 influenza			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infection			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza			

subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngitis			
subjects affected / exposed	2 / 368 (0.54%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngitis viral			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymph gland infection			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningococcal sepsis			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis media			
subjects affected / exposed	1 / 368 (0.27%)	2 / 271 (0.74%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis media acute			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngitis			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumococcal bacteraemia			

subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumococcal infection			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumococcal sepsis			
subjects affected / exposed	0 / 368 (0.00%)	1 / 271 (0.37%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	2 / 368 (0.54%)	1 / 271 (0.37%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia bacterial			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia respiratory syncytial viral			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis			
subjects affected / exposed	2 / 368 (0.54%)	1 / 271 (0.37%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis acute			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory syncytial virus bronchiolitis			

subjects affected / exposed	1 / 368 (0.27%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory syncytial virus bronchitis			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory syncytial virus infection			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection viral			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal sepsis			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonsillitis			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheitis			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory tract infection			

subjects affected / exposed	1 / 368 (0.27%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	1 / 368 (0.27%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral infection			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacteraemia			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eczema infected			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Exanthema subitum			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis norovirus			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hand-foot-and-mouth disease			

subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impetigo			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lobar pneumonia			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mastoiditis			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parainfluenzae virus infection			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic arthritis streptococcal			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varicella			

subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea infectious			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia sepsis			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis media fungal			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia viral			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Roseola			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rotavirus infection			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	0 / 368 (0.00%)	1 / 271 (0.37%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis orbital			

subjects affected / exposed	1 / 368 (0.27%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 368 (0.00%)	1 / 271 (0.37%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subcutaneous abscess			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Type 1 diabetes mellitus			
subjects affected / exposed	0 / 368 (0.00%)	1 / 271 (0.37%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Weight gain poor			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dehydration			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemia			
subjects affected / exposed	0 / 368 (0.00%)	0 / 271 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	10Pn3+1-6W-6M/053 Group	Ctrl3+1-6W-6M/053 Group	10Pn2+1-6W-6M/053 Group
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1697 / 1849 (91.78%)	861 / 1069 (80.54%)	1118 / 1316 (84.95%)
General disorders and administration site conditions			
Pain - PRI			
alternative assessment type: Systematic			
subjects affected / exposed ^[1]	1163 / 1846 (63.00%)	253 / 1067 (23.71%)	790 / 1303 (60.63%)
occurrences (all)	1163	253	790
Redness – PRI			
alternative assessment type: Systematic			
subjects affected / exposed ^[2]	1414 / 1846 (76.60%)	479 / 1067 (44.89%)	923 / 1303 (70.84%)
occurrences (all)	1414	479	923
Swelling - PRI			
alternative assessment type: Systematic			
subjects affected / exposed ^[3]	1098 / 1846 (59.48%)	259 / 1067 (24.27%)	707 / 1303 (54.26%)
occurrences (all)	1098	259	707
Drowsiness - PRI			
alternative assessment type: Systematic			
subjects affected / exposed ^[4]	1395 / 1846 (75.57%)	658 / 1067 (61.67%)	909 / 1303 (69.76%)
occurrences (all)	1395	658	909
Irritability – PRI			
alternative assessment type: Systematic			
subjects affected / exposed ^[5]	1697 / 1846 (91.93%)	861 / 1067 (80.69%)	1118 / 1303 (85.80%)
occurrences (all)	1697	861	1118
Loss of appetite – PRI			
alternative assessment type: Systematic			
subjects affected / exposed ^[6]	858 / 1846 (46.48%)	409 / 1067 (38.33%)	521 / 1303 (39.98%)
occurrences (all)	858	409	521
Temperature ≥ 38.0°C (Rectally) – PRI			
alternative assessment type: Systematic			
subjects affected / exposed ^[7]	819 / 1846 (44.37%)	240 / 1067 (22.49%)	521 / 1303 (39.98%)
occurrences (all)	819	240	521

Pain - BST alternative assessment type: Systematic subjects affected / exposed ^[8] occurrences (all)	888 / 1758 (50.51%) 888	250 / 1024 (24.41%) 250	710 / 1258 (56.44%) 710
Redness – BST alternative assessment type: Systematic subjects affected / exposed ^[9] occurrences (all)	913 / 1758 (51.93%) 913	345 / 1024 (33.69%) 345	702 / 1258 (55.80%) 702
Swelling - BST alternative assessment type: Systematic subjects affected / exposed ^[10] occurrences (all)	716 / 1758 (40.73%) 716	229 / 1024 (22.36%) 229	586 / 1258 (46.58%) 586
Drowsiness - BST alternative assessment type: Systematic subjects affected / exposed ^[11] occurrences (all)	721 / 1757 (41.04%) 721	307 / 1024 (29.98%) 307	561 / 1257 (44.63%) 561
Irritability - BST alternative assessment type: Systematic subjects affected / exposed ^[12] occurrences (all)	1124 / 1757 (63.97%) 1124	491 / 1024 (47.95%) 491	816 / 1257 (64.92%) 816
Loss of appetite – BST alternative assessment type: Systematic subjects affected / exposed ^[13] occurrences (all)	549 / 1757 (31.25%) 549	260 / 1024 (25.39%) 260	411 / 1257 (32.70%) 411
Temperature ≥ 38.0°C (Rectally) – BST alternative assessment type: Systematic subjects affected / exposed ^[14] occurrences (all)	391 / 1757 (22.25%) 391	142 / 1024 (13.87%) 142	333 / 1257 (26.49%) 333
Injection site induration - PRI subjects affected / exposed occurrences (all)	376 / 1849 (20.34%) 376	47 / 1069 (4.40%) 47	203 / 1316 (15.43%) 203
Pyrexia - PRI			

subjects affected / exposed occurrences (all)	0 / 1849 (0.00%) 0	0 / 1069 (0.00%) 0	0 / 1316 (0.00%) 0
Injection site induration - BST subjects affected / exposed ^[15] occurrences (all)	118 / 1786 (6.61%) 118	29 / 1043 (2.78%) 29	81 / 1275 (6.35%) 81
Gastrointestinal disorders			
Diarrhoea - PRI subjects affected / exposed occurrences (all)	106 / 1849 (5.73%) 106	65 / 1069 (6.08%) 65	52 / 1316 (3.95%) 52
Teething - PRI subjects affected / exposed occurrences (all)	48 / 1849 (2.60%) 48	40 / 1069 (3.74%) 40	14 / 1316 (1.06%) 14
Respiratory, thoracic and mediastinal disorders			
Cough - PRI subjects affected / exposed occurrences (all)	42 / 1849 (2.27%) 42	30 / 1069 (2.81%) 30	18 / 1316 (1.37%) 18
Infections and infestations			
Gastroenteritis - PRI subjects affected / exposed occurrences (all)	0 / 1849 (0.00%) 0	0 / 1069 (0.00%) 0	0 / 1316 (0.00%) 0
Nasopharyngitis - PRI subjects affected / exposed occurrences (all)	84 / 1849 (4.54%) 84	48 / 1069 (4.49%) 48	26 / 1316 (1.98%) 26
Otitis media - PRI subjects affected / exposed occurrences (all)	55 / 1849 (2.97%) 55	42 / 1069 (3.93%) 42	16 / 1316 (1.22%) 16
Rhinitis - PRI subjects affected / exposed occurrences (all)	121 / 1849 (6.54%) 121	90 / 1069 (8.42%) 90	57 / 1316 (4.33%) 57
Upper respiratory tract infection - PRI subjects affected / exposed occurrences (all)	172 / 1849 (9.30%) 172	98 / 1069 (9.17%) 98	74 / 1316 (5.62%) 74
Upper respiratory tract infection - BST subjects affected / exposed ^[16] occurrences (all)	89 / 1849 (4.81%) 89	47 / 1069 (4.40%) 47	47 / 1316 (3.57%) 47

Non-serious adverse events	Ctrl2+1-6W-6M/053 Group	10Pn7-11M/053 Group	Ctrl7-11M/053 Group
Total subjects affected by non-serious adverse events			
subjects affected / exposed	615 / 859 (71.59%)	191 / 241 (79.25%)	134 / 204 (65.69%)
General disorders and administration site conditions			
Pain - PRI			
alternative assessment type: Systematic			
subjects affected / exposed ^[1]	159 / 852 (18.66%)	148 / 237 (62.45%)	58 / 202 (28.71%)
occurrences (all)	159	148	58
Redness - PRI			
alternative assessment type: Systematic			
subjects affected / exposed ^[2]	303 / 852 (35.56%)	165 / 237 (69.62%)	77 / 202 (38.12%)
occurrences (all)	303	165	77
Swelling - PRI			
alternative assessment type: Systematic			
subjects affected / exposed ^[3]	127 / 852 (14.91%)	138 / 237 (58.23%)	29 / 202 (14.36%)
occurrences (all)	127	138	29
Drowsiness - PRI			
alternative assessment type: Systematic			
subjects affected / exposed ^[4]	472 / 852 (55.40%)	135 / 237 (56.96%)	89 / 202 (44.06%)
occurrences (all)	472	135	89
Irritability - PRI			
alternative assessment type: Systematic			
subjects affected / exposed ^[5]	615 / 852 (72.18%)	191 / 237 (80.59%)	134 / 202 (66.34%)
occurrences (all)	615	191	134
Loss of appetite - PRI			
alternative assessment type: Systematic			
subjects affected / exposed ^[6]	248 / 852 (29.11%)	118 / 237 (49.79%)	86 / 202 (42.57%)
occurrences (all)	248	118	86
Temperature ≥ 38.0°C (Rectally) - PRI			
alternative assessment type: Systematic			
subjects affected / exposed ^[7]	140 / 852 (16.43%)	73 / 237 (30.80%)	36 / 202 (17.82%)
occurrences (all)	140	73	36
Pain - BST			
alternative assessment type:			

Systematic			
subjects affected / exposed ^[8]	171 / 827 (20.68%)	123 / 216 (56.94%)	40 / 188 (21.28%)
occurrences (all)	171	123	40
Redness – BST			
alternative assessment type: Systematic			
subjects affected / exposed ^[9]	238 / 827 (28.78%)	106 / 216 (49.07%)	54 / 188 (28.72%)
occurrences (all)	238	106	54
Swelling - BST			
alternative assessment type: Systematic			
subjects affected / exposed ^[10]	118 / 827 (14.27%)	85 / 216 (39.35%)	31 / 188 (16.49%)
occurrences (all)	118	85	31
Drowsiness - BST			
alternative assessment type: Systematic			
subjects affected / exposed ^[11]	243 / 827 (29.38%)	92 / 216 (42.59%)	47 / 188 (25.00%)
occurrences (all)	243	92	47
Irritability - BST			
alternative assessment type: Systematic			
subjects affected / exposed ^[12]	410 / 827 (49.58%)	129 / 216 (59.72%)	84 / 188 (44.68%)
occurrences (all)	410	129	84
Loss of appetite – BST			
alternative assessment type: Systematic			
subjects affected / exposed ^[13]	186 / 827 (22.49%)	64 / 216 (29.63%)	46 / 188 (24.47%)
occurrences (all)	186	64	46
Temperature ≥ 38.0°C (Rectally) – BST			
alternative assessment type: Systematic			
subjects affected / exposed ^[14]	120 / 827 (14.51%)	42 / 216 (19.44%)	11 / 188 (5.85%)
occurrences (all)	120	42	11
Injection site induration - PRI			
subjects affected / exposed	19 / 859 (2.21%)	27 / 241 (11.20%)	2 / 204 (0.98%)
occurrences (all)	19	27	2
Pyrexia - PRI			
subjects affected / exposed	0 / 859 (0.00%)	25 / 241 (10.37%)	20 / 204 (9.80%)
occurrences (all)	0	25	20
Injection site induration - BST			

subjects affected / exposed ^[15] occurrences (all)	15 / 837 (1.79%) 15	8 / 226 (3.54%) 8	3 / 197 (1.52%) 3
Gastrointestinal disorders			
Diarrhoea - PRI			
subjects affected / exposed	39 / 859 (4.54%)	17 / 241 (7.05%)	16 / 204 (7.84%)
occurrences (all)	39	17	16
Teething - PRI			
subjects affected / exposed	20 / 859 (2.33%)	10 / 241 (4.15%)	18 / 204 (8.82%)
occurrences (all)	20	10	18
Respiratory, thoracic and mediastinal disorders			
Cough - PRI			
subjects affected / exposed	21 / 859 (2.44%)	7 / 241 (2.90%)	9 / 204 (4.41%)
occurrences (all)	21	7	9
Infections and infestations			
Gastroenteritis - PRI			
subjects affected / exposed	0 / 859 (0.00%)	11 / 241 (4.56%)	13 / 204 (6.37%)
occurrences (all)	0	11	13
Nasopharyngitis - PRI			
subjects affected / exposed	35 / 859 (4.07%)	15 / 241 (6.22%)	10 / 204 (4.90%)
occurrences (all)	35	15	10
Otitis media - PRI			
subjects affected / exposed	13 / 859 (1.51%)	23 / 241 (9.54%)	16 / 204 (7.84%)
occurrences (all)	13	23	16
Rhinitis - PRI			
subjects affected / exposed	49 / 859 (5.70%)	21 / 241 (8.71%)	32 / 204 (15.69%)
occurrences (all)	49	21	32
Upper respiratory tract infection - PRI			
subjects affected / exposed	29 / 859 (3.38%)	28 / 241 (11.62%)	42 / 204 (20.59%)
occurrences (all)	29	28	42
Upper respiratory tract infection - BST			
subjects affected / exposed ^[16]	21 / 859 (2.44%)	13 / 241 (5.39%)	11 / 204 (5.39%)
occurrences (all)	21	13	11

Non-serious adverse events	10Pn12-18M/053 Group	Ctrl12-18M/053 Group	
Total subjects affected by non-serious adverse events			

subjects affected / exposed	300 / 368 (81.52%)	174 / 271 (64.21%)	
General disorders and administration site conditions			
Pain - PRI			
alternative assessment type: Systematic			
subjects affected / exposed ^[1]	300 / 363 (82.64%)	116 / 270 (42.96%)	
occurrences (all)	300	116	
Redness – PRI			
alternative assessment type: Systematic			
subjects affected / exposed ^[2]	265 / 363 (73.00%)	129 / 270 (47.78%)	
occurrences (all)	265	129	
Swelling - PRI			
alternative assessment type: Systematic			
subjects affected / exposed ^[3]	209 / 363 (57.58%)	42 / 270 (15.56%)	
occurrences (all)	209	42	
Drowsiness - PRI			
alternative assessment type: Systematic			
subjects affected / exposed ^[4]	214 / 363 (58.95%)	118 / 270 (43.70%)	
occurrences (all)	214	118	
Irritability – PRI			
alternative assessment type: Systematic			
subjects affected / exposed ^[5]	282 / 363 (77.69%)	140 / 270 (51.85%)	
occurrences (all)	282	140	
Loss of appetite – PRI			
alternative assessment type: Systematic			
subjects affected / exposed ^[6]	190 / 363 (52.34%)	117 / 270 (43.33%)	
occurrences (all)	190	117	
Temperature ≥ 38.0°C (Rectally) – PRI			
alternative assessment type: Systematic			
subjects affected / exposed ^[7]	110 / 363 (30.30%)	38 / 270 (14.07%)	
occurrences (all)	110	38	
Pain - BST			
alternative assessment type: Systematic			
subjects affected / exposed ^[8]	0 / 1 (0.00%)	0 / 1 (0.00%)	
occurrences (all)	0	0	

Redness – BST alternative assessment type: Systematic subjects affected / exposed ^[9] occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	
Swelling - BST alternative assessment type: Systematic subjects affected / exposed ^[10] occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	
Drowsiness - BST alternative assessment type: Systematic subjects affected / exposed ^[11] occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	
Irritability - BST alternative assessment type: Systematic subjects affected / exposed ^[12] occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	
Loss of appetite – BST alternative assessment type: Systematic subjects affected / exposed ^[13] occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	
Temperature ≥ 38.0°C (Rectally) – BST alternative assessment type: Systematic subjects affected / exposed ^[14] occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	
Injection site induration - PRI subjects affected / exposed occurrences (all)	45 / 368 (12.23%) 45	2 / 271 (0.74%) 2	
Pyrexia - PRI subjects affected / exposed occurrences (all)	14 / 368 (3.80%) 14	26 / 271 (9.59%) 26	
Injection site induration - BST subjects affected / exposed ^[15] occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	
Gastrointestinal disorders			

Diarrhoea - PRI subjects affected / exposed occurrences (all)	26 / 368 (7.07%) 26	25 / 271 (9.23%) 25	
Teething - PRI subjects affected / exposed occurrences (all)	9 / 368 (2.45%) 9	7 / 271 (2.58%) 7	
Respiratory, thoracic and mediastinal disorders Cough - PRI subjects affected / exposed occurrences (all)	14 / 368 (3.80%) 14	15 / 271 (5.54%) 15	
Infections and infestations Gastroenteritis - PRI subjects affected / exposed occurrences (all)	0 / 368 (0.00%) 0	0 / 271 (0.00%) 0	
Nasopharyngitis - PRI subjects affected / exposed occurrences (all)	18 / 368 (4.89%) 18	10 / 271 (3.69%) 10	
Otitis media - PRI subjects affected / exposed occurrences (all)	25 / 368 (6.79%) 25	22 / 271 (8.12%) 22	
Rhinitis - PRI subjects affected / exposed occurrences (all)	29 / 368 (7.88%) 29	25 / 271 (9.23%) 25	
Upper respiratory tract infection - PRI subjects affected / exposed occurrences (all)	36 / 368 (9.78%) 36	40 / 271 (14.76%) 40	
Upper respiratory tract infection - BST subjects affected / exposed ^[16] occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	

Notes:

[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Assessment of solicited symptoms and unsolicited AEs was done on subjects with results/who received the indicated vaccination (PRI or BST).

[2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Assessment of solicited symptoms and unsolicited AEs was done on subjects with results/who received the indicated vaccination (PRI or BST).

Justification: Assessment of solicited symptoms and unsolicited AEs was done on subjects with results/who received the indicated vaccination (PRI or BST).

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
11 December 2008	Protocol amendment 1, dated 11 December 2008, implemented the following: 1) Addition of 6 clusters located in municipalities where no agreement from the health care center responsible for the municipality primary health care and well-baby clinics had been obtained for participation in the 10PN-PD-DIT-043 study (i.e. Espoo, Vantaa and surroundings municipalities); 2) The addition of a nasopharyngeal swab sampling at the pre-vaccination time point for subjects enrolled within the first 7 months of life and who were part of the Immuno subset and for all subjects enrolled between 7-11 months of age.; 3) Recording of Bacille Calmette Guerin (BCG) vaccination since birth up to 30 days before the first study vaccination; 4) The addition of a sample size justification for acute otitis media (AOM) endpoint; 5) The addition of Infanrix Polio+Hib vaccine as a non-study vaccine to be offered to all subjects in order to comply with the national immunization recommendations; 6) The addition of Rotarix as a non-study vaccine to be offered to children within the first 6 months of life; 7) Physical examination was made optional after Visit 1 (screening), 8) Attribution of a treatment number was added as a study procedure for each vaccination visit.
18 February 2009	Protocol amendment 2, dated 18 February 2009, implemented the following changes: 1) Addition of collection of data on respiratory tract infections (RTIs), including detailed acute otitis media (AOM) diagnosis data in a subset of subjects in Turku area; 2) Inclusion of municipalities surrounding Oulu in the list of municipalities where no collaboration with health care centers had been set up in study 10PN-PD-DIT-043 but where there was opportunity for parent(s)/LARs to let their child participate in study 10PN-PD-DIT-053 (i.e. Espoo, Vantaa and surroundings municipalities and municipalities surrounding Oulu); 3) The National Public Health Institute (KTL) and the National Research and Development Centre for Welfare and Health (STAKES) had merged to the National Institute for Health and Welfare (THL); 4) Clarification was added in some tables concerning the age at enrolment; 5) Correction of the interval between some study visits; 6) Wording concerning the Immuno subset was changed to ensure that the subjects in this subset would be enrolled according to the age and treatment groups; 6) Deletion of the specification of the injection side.
17 November 2009	Protocol amendment 3, dated 17 November 2009, implemented the following change. Because a higher number of non-evaluable subjects for according-to-protocol (ATP) analysis due to the flu pandemic in 2009 was anticipated and the recruitment rate was lower than expected, especially in the catch-up cohorts (7-18 months of age at enrolment), the target numbers of subjects to be recruited per age group was changed and the recruitment time was extended in order to secure the AOM objective which was related to the infant vaccination cohort (< 7 months of age at enrolment) based on the ATP cohort.

12 August 2011	<p>Protocol amendment 4, dated 12 August 2011, was developed for the following reasons: 1) The conditions for triggering IPD effectiveness analysis in this study were linked to the 10PN-PD-DIT-043 study. As the 10PN-PD-DIT-043 study enrolment reached only 50% of the initial recruitment plan, there was a need to redefine the conditions for triggering IPD effectiveness analysis in that study. Consequently, this change was reflected in the 10PN-PD-DIT-053 protocol; 2) In order to align the timing of unblinding (planned after cleaning of the clinical database from both studies) with the 10PN-PD-DIT-043 study, the age range for the last study visit for subjects enrolled between 6 weeks and 6 months of age was enlarged from 21-22 months of age to 18-22 months of age; 3) The protocol was adjusted to reflect the Independent Data Monitoring Committee (IDMC) recommendation to evaluate the chest X-rays from the hospital-diagnosed pneumonia cases in this study by an independent review panel according to WHO guidelines for study purposes, as in the 10PN-PD-DIT-043 study; 4) GSK Biologicals had decided to maintain pneumococcal enzyme-linked immunosorbent assay (ELISA) testing but not to perform the pneumococcal opsonophagocytic activity (OPA) and anti-protein D ELISA testing in the 7-11 and 12-18 months of age groups part of the immuno subset for the following reasons: a) The WHO considers the antibody concentration measured by the ELISA assay as the main licensure criterion for new pneumococcal conjugate vaccines and the outcome of the OPA testing on samples obtained one month post-primary vaccination as supportive for licensure, b) These tests in the catch-up groups were not linked to the primary objective of the study, i.e. IPD effectiveness in the infant cohort; 5) Further details on microbiological testing were included and additional minor corrections were done.</p>
----------------	--

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

This study is nested in 2008-005149-48; the study population included subjects of both studies. Due to the technical complexity to present results for a nested study, secondary outcomes are presented in the attached PDF file.

Notes: